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SIMPLE AND RAPID ENZYMATIC METHOD FOR THE SYNTHESIS
OF SINGLE-STRAND OLIGONUCLEOTIDES CONTAINING
TRIFLUOROTHYMIDINE
Norihiko Suzuki and Masakazu Fukushima
Tokushima Research Center, Taiho Pharmaceutical Co., Ltd., Kawauchi, Tokushima, Japan
 To investigate the mechanism of triﬂuorothymidine (TFT)-induced DNA damage, we devel-
oped an enzymatic method for the synthesis of single-strand oligonucleotides containing TFT-
monophosphate residues. Sixteen-mer oligonucleotides and 14-mer 5 -phosphorylated oligonu-
cleotides were annealed to the template of 25-mer, so as to empty one nucleotide site. TFT-triphosphate
was incorporated into the site by DNA polymerase and then ligated to 5 -phosphorylated oligonu-
cleotides by DNA ligase. The synthesized 31-mer oligonucleotides containing TFT residues were
isolated from the 25-mer complementary template by denaturing polyacrylamide electrophoresis. Us-
ing these single-strand oligonucleotides containing TFT residues, the cleavage of TFT residues from
DNA, using mismatch uracil-DNA glycosylase (MUG) of E.coli origin, was compared with that of
5-ﬂuorouracil (5FU) and 5-bromodeoxyuridine (BrdU). The TFT/A pair was not cleaved by MUG,
while the other pairs, namely, 5FU/A, 5FU/G, BrdU/A, BrdU/G, and TFT/G, were easily cleaved
from each synthesized DNA. Thus, this method is useful for obtaining some site-speciﬁcally modiﬁed
oligonucleotides.
Keywords TFT; triﬂuorothymidine; 5-triﬂuormethyl-2 -deoxyuridine; 5-ﬂuorouracil 5-
ﬂuoro-2 -deoxyuridine; oligonucleotide
INTRODUCTION
Triﬂuorothymidine (TFT), which is a component of the oral drug for-
mulation TAS-102, is known to inhibit thymidylate synthase and to be in-
corporated into the DNA, similar to 5-ﬂuorouracil (5FU) or 5-ﬂuoro-2 -
deoxyuridine (FdUrd).
TheefﬁcacyofTAS-102asanoralchemotherapeuticagentformetastatic
gastrointestinal cancer is currently under investigation in phase I/II clinical
trials.[1] We demonstrated that short-term high-dose exposure to TFT in-
creased its incorporation into DNA and resulted in potent antitumor activity
against human cancer cells, both those sensitive and resistant to 5FU.[2,3]
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Therefore, it is necessary to investigate the mode of action of TFT against
DNA replication and repair enzymes, as compared with that of 5FU and
FdUrd. The incorporation of commercially available TFT into DNA using
phosphoramidite chemistry[4,5] has been reported. However, after a trityl-on
oligonucleotidewassynthesizedinthesolidphase,thetriﬂuoromethylatthe
5-position in the base converted to nitrile under the standard deprotection
condition (concd NH4OH at 55◦C for 16 hours)[6]. These results indicated
that the conversion was due to the known reactivity and instability of the
triﬂuoromethyl group of 5-triﬂuoromethyluracil toward nucleophiles under
basic conditions. Holzberger et al.[7] reported that when triﬂuorothymidine
triphosphate(TFT-TP)wassynthesized,itsnucleotidecouldbeincorporated
into the DNA by some DNA polymerases. In order to examine the mode of
action of several analogues incorporated into the DNA, it is necessary to use
single-strand oligonucleotide site-speciﬁc incorporation of these analogues.
Therefore,thepresentstudydescribestheestablishmentofamethodforthe
generation of single-strand oligonucleotides containing TFT residues for in-
vestigating of the effect of TFT against DNA repair and replication enzymes.
MATERIALS AND METHODS
Reagents
5-Triﬂuorothymidine-5 -triphosphate (TFT-TP) was synthesized by con-
tract research with Moravek Biochemical Inc. (USA). [Gamma-32P]
adenosine 5 -triphosphate, tetra (triethylammonium) salt (111 TBq/mmol,
NEG502A) was purchased from Perkin Elmer Company (USA).
Enzymes and Oligonucleotides
Sequenase, a version 2.0 DNA polymerase was purchased from USB
Corporation (USA). Pfu DNA polymerase was purchased from Fermentas
life Sciences (USA). Klenow fragment (3  → 5  exonuclease minus and 5  →
3  exonuclease minus) was purchased from New England BioLabs (USA).
mismatch uracil-DNA glycosylase (MUG) was purchased from Trevigen Inc.
(USA). Oligonucleotides containing 5FU, BrdU, U, and other normal bases
were purchased from Sigma Chemical Co., as gel-puriﬁed grade chemicals
(Japan).
Primer Extension Assay
The 17-base primer was labeled with 32Pa ti t s5  -end and annealed to its
complementary M13mp18(+) DNA template.
(5 ) 32P- GTAAAACGACGGCCAGT
(3 ) CATTTTGCTGCCGGTCACGGTTCGAACGTACGGACGT898 N. Suzuki and M. Fukushima
The DNA primer extension assay[8,9] was carried out in a total volume
of 10 µL, containing 2.5 pmole primer/template, DNA polymerase, and
dNTP mixture (containing or not containing FTP-triphosphate), at 37◦C
for 30 minutes. The reaction was stopped by adding 3.3 µL denaturing
loading buffer (95% formamide/10 mM EDTA/0.1%BPB/0.1%XC). The
mixture was boiled at 100◦C for 3 minutes and cooled on ice. The elec-
trophoresis and the subsequent analysis was performed using the BAS2000
system.
Synthesis of Oligonucleotides Containing TFT
A 16-mer oligonucleotide (DNA(a)) and 14-mer 5 -phosphorylated
oligonucleotide (DNA(b)) were annealed with a 25-mer oligonucleotide
(DNA(c)) as the template as described below.
DNA(a); 5 -GACTAGTCTGCATGCC-3 
DNA(b); 5  P-ACGTACGTTGCATG-3 
DNA(c); 5 -GCAACGTACGTAGGCATGCAGACTA-3 
Thereactionmixture(2.26mL)containing30nmolofDNA(a),40nmol
of DNA(b), 40 nmol of DNA(c), 2 µmol of TFT triphosphate (TFT-TP), and
800 U of sequenase in 20 mM Tris-HCl, pH 7.5, 10 mM MgCl2 and 25 mM
NaCl was incubated at 37◦C for 30 minutes; then, 200 µL of T4 DNA ligase
(Nippon Gene Co., Ltd., Japan) and 280 µL of 10 x ligation buffer (500 mM
Tris-HCl, 100 mM MgCl2, 200 mM DTT, and 10 mM ATP) were added to
the mixture. The reactions were allowed to proceed for 30 minutes at room
temperature. The reaction products were concentrated by the addition of
butanolandprecipitatedbyethanol.TheDNAcrudesolutionwaspuriﬁedby
electrophoresison15%polyacrylamidegelscontainingTBEbuffer(100mM
Tris.pH 8.3, 100 mM borate, 2 mM EDTA, 8M urea).
Analysis of Oligonucleotides Containing TFT
The purity of the modiﬁed synthetic DNA fragments was checked by
polyacrylamide gel electrophoresis and HPLC.
To cleave the phosphodiester bonds, DNA was treated with 5 units of
nuclease P1 (Sigma-Aldrich Corp., USA) in 0.05 mM Tris-HCl, pH 6.0, in
the presence of 0.5 mM NaCl at 37◦C for 1 hour. And then the reaction
mixture was treated with alkaline phosphatase (Takara, Japan) in 0.1 mM
Tris-HCl, pH 8.0, 0.25 mM NaCl, 1 mM MgCl2 at 37◦C for 1 hour. With this
treatment, all the nucleotides were dephosphorylated to nucleosides. The
resolved nucleosides were analyzed using an HPLC system (Gulliver HPLC
system, Jasco Co., Ltd., Japan).Novel Method for TFT-Containing Oligonucleotide Synthesis 899
DNA Glycosylase Assay
Oligomers(31-mer)containingaTFT-monophosphateorotherdeoxyri-
bonucleotidewerelabeledwith 32Pattheir5 -endandannealedtotheircom-
plementary 31-base templates. The DNA glycosylase assay[10] was carried out
in a total volume of 10 µL containing 2.5 pmole primer/template, mismatch
uracil-DNA glycosylase (MUG) in 20 mmol/L Tris, 1 mmol/L EDTA, and 50
mmol/L NaCl, the reactions being allowed to proceed at 37◦C for 60 min-
utes.Thereactionswerestopped,followedbytreatmentwith100mMNaOH
at 90◦C for 15 minutes, in order to cleave the sugar-phosphate backbone at
theAPsite.Thelabeledoligonucleotideswereprecipitatedwith3timestheir
volumes of ethanol at −80◦C for 10 hours and dissolved in 10 µLo f5 0m M
Tris(pH8.0)and5mMMgCl2.Thissamplewasaddedto3.3µLofthedena-
turing loading buffer (95% formamide/10 mM EDTA/0.1%BPB/0.1%XC),
boiled at 100◦C for 3 minutes,and then cooled on ice. The reaction products
were separated by 15% polyacrylamide sequencing gel electrophoresis and
analyzed using the BAS20000 system.
A31-mer 32Plabeleddrug-containingornormaloligomer(DNA(1))and
31-mer oligomer (DNA(2) or DNA(3)) were also prepared:
DNA(1); ∗5 -GACTAGTCTGCATGCCXACGTACGTTGCATG-3 
where X is U, T(DNA(1)[T]), TFT(DNA(1)[TFT]), 5BrU or 5FU.
DNA(2); 5 -CATGCAACGTACGTAGGCATGCAGACTAGTC -3 
DNA(3); 5 -CATGCAACGTACGTGGGCATGCAGACTAGTC -3 
Electrophoresis and Autoradiography
Products from the DNA synthesis and ligation reactions were analyzed by
electrophoresison15%polyacrylamidegelscontainingTBEbuffer(100mM
Tris.pH 8.3, 100 mM borate, 2 mM EDTA, 8 M urea) at 1500V for 2–3 hours.
Autoradiographywasperformedfor2–10hoursusingtheFujixBAS2000
system (Fuji Photo-Film, Tokyo, Japan).
RESULTS
Analysis of Synthesized TFT-Containing Oligonucleotide
Thesynthesizedtriﬂuorothymidine-triphosphate(TFT-TP)wasanalyzed
by mass spectrometry (Figure 1). TFT-TP was detected as the peak corre-
sponding to 535.16 m/z.
Incorporation TFT into DNA by Several DNA Polymerases
DNAprimerextensionassaywasusedtomeasuretheactivityoftheincor-
poratedTFT-TPintoDNAbyseveralcommercialavailableDNApolymerases
(Figure 2).900 N. Suzuki and M. Fukushima
FIGURE 1 MassspectrumofTFT-TP.Mass-analysiswasperformedusinganESIsourceinnegativemode.
The acquired m/z was from 435.00 to 635.00. The ionization parameters were capillary voltage, -47.5V;
source voltage, 3.02 kV; capillary temperature, 233.50◦C.
FIGURE 2 Incorporation TFT into DNA by several DNA polymerases. Actions of TFT and BrdU on
DNA primer extension in vitro. The ability of pfu DNA polymerase (pfu, 2.5 U/10 µL), Sequenase DNA
polymerase (Sequenase, 13 U/10 µL), and Klenow fragment DNA polymerase (Klenow, 2.0 U/10 µL)
to extend the 5 -32P-labeled primer/M13mp19(+)D N A( 5µg/mL) was evaluated in the presence of
dATP,dGTP, and dCTP with or without dTTP, with TFT-TP, and with BrdUTP. Lanes 1–4, dideoxynu-
cleotide sequencing of the M13mp19(+) DNA template with ddGTP, ddATP, ddTTP, and ddCTP,
respectively, are indicated.Novel Method for TFT-Containing Oligonucleotide Synthesis 901
When dTTP was omitted from the mixture (T-reaction), the primer was
elongated by sequenase DNA polymerase and klenow fragment DNA poly-
merase,whichpausedattheTsite,butnotbypfuDNApolymerase(Figure2,
lanes 5, 10, and 13). These results suggest the error-prone property of these
enzymes.[11] Sequenase DNA polymerase and klenow fragment DNA poly-
merasewereabletoincorporateTFT-TPintoDNA,butpfuDNApolymerase
showed little activity in this situation.
Enzymatic Synthesis of Oligonucleotides Containing TFT
In order to investigate the actions of TFT on the DNA replication and re-
pair enzymes, 31-mer oligonucleotides containing TFT were synthesized en-
zymatically (Figure 3). First, for the DNA polymerase reaction step, we used
sequenase DNA polymerase, as shown in Figure 2. TFT-TP was completely
incorporated into the nucleotide site (T-site) between the 16-mer oligonu-
cleotides and 5 -phosphorylated 14-mer oligonucleotides within 10 minutes.
This reaction does not allow elongation of more than one nucleotide site,
becausethepre-annealed5 -phosphorylated14-meroligonucleotideshinder
the next elongation.
Second, in the DNA ligase reaction step, if TFT were not incorpo-
rated into the T-site or were incorporated in more than one nucleotide
site, then DNA ligase would not be able to connect its oligomers with
the 5 -phosphorylated 14-mer oligonucleotides. Therefore, the synthesized
31-mer oligomer appears to be site-speciﬁcally incorporated into the TFT-
monophosphate residues.
Third, we puriﬁed these oligonucleotides by denaturing polyacrylamide
electrophoresis. At this step, we did not use ethidium bromide to stain the
DNA, because the band of the 31-mer oligomer was immediately detected
by direct UV irradiation from a UV lamp.
FIGURE 3 Enzymatic reaction of DNA polymerase and DNA ligase. Sixteen-mer oligonucleotides were
labeled with 32P and aliquots (0.05 pmol/µL) were added to the reaction mixture for monitoring
the enzymatic reaction. Except adding the 32P labeled oligonucleotides, the same experiments were
performed as described in synthesis oligonucleotides containing TFT section of Materials and Methods).902 N. Suzuki and M. Fukushima
FIGURE 4 Analysis of oligonucleotide containing TFT using high-performance liquid chromatography.
OligonucleotidescontainingTFTwereresolvedintonucleosidesbythetreatmentwithphosphodiesterase
and alkaline phosphatase as described in Material and Methods. Aliquots (50 µL) of the treated samples
were applied to a Chemcosorb 300-5C18 column (4.6 i.d. × 250 mm, Chemco Corp., Ltd.) under the
following chromatographic conditions: mobile phase, 2% acetonitrile containing 0.01% triﬂuoroacetic
acid; ﬂow rate, 1.ml/min;monitoring wavelength, 254 nm.
Analysis of the Synthesized Oligonucleotides Containing TFT
The oligonucleotides were digested by nuclease P1 and alkaline phos-
phatase and were conﬁrmed to show the TFT peak in the HPLC (Figure 4).
Excision Activity by E. coli Mismatch Uracil-DNA Glycosylase
of TFT-Containing Oligonucleotides
In order to investigate the cleavage activity of TFT residues by E. coli mis-
match uracil-DNA glycosylase (MUG), single-strand oligonucleotides con-
taining TFT monophosphate residues and complementary oligonucleotides
(TFT/A pair or TFT/G pair) were prepared (Figure 5). MUG (4 unit)
FIGURE 5 Cleavage by E. coli mismatch uracil-DNA glycosylase (MUG) of oligonucleotides containing
several5-substitutedpyrimidinenucleotideresidues.Lanes1–5showcleavageofadouble-strandoligonu-
cleotide with several 5-substituted pyrimidine nucleotide residues paired to the adenine base, and lanes
6–10 show the same sequence with the analogues paired to the guanine base. The oligonulcleotides
(0.125 pmol/µl) were incubated with 4.0 units of MUG at 37◦C for 60 minutes.Novel Method for TFT-Containing Oligonucleotide Synthesis 903
excised not only the U/G pair, but also the U/A pair following incubation at
37◦C for 1 hour. These results were consistent with a previous report.[12] Un-
der these conditions, all of the 5FU/A, 5FU/G, and BrdU/G, BrdU/A, and
TFT/G pairs were removed, but not the TFT/A pair. These studies indicate
that MUG does not have the ability to recognize and remove TFT paired to
adenine in the double-strand DNA.
DISCUSSION
5-Fluorouracil (5FU) an antitumor pyrimidine, has been widely used for
the treatment of gastric, colorectal, head and neck and breast cancers. Like
5FU,TFTisbelievedtoexertitscytocidaleffectbyinhibitingTS.[13]However,
we found that when tumors were exposed to high concentrations of TFT for
short periods of time, the drug was incorporated into the DNA and exerted
its cytocidal activity by causing DNA fragmentation rather than by inhibiting
TS.[2,3, 14] Therefore, we considered it necessary to prepare oligonucleotides
to investigate with the mode of action of triﬂuorothymidine (TFT) against
DNA replication and repair enzymes as compared to 5FU.
We succeeded in synthesizing single-strand oligonucleotides containing
TFT-monophosphate residues using DNA polymerase and DNA ligase, but
failed to synthesize these oligonucleotides using the principle of phospho-
ramidite chemistry[6] (data not shown). We used a simple and rapid method
in the present study, making use of enzymatic reactions under physiological
conditions.
E. coli mismatch uracil-DNA glycosylase (MUG) can remove 5FU/A,
5FU/G, and 5-bromodeoxyuridine (BrdU)/G, BrdU/A,and TFT/G pairs,
but not the TFT/A pair.
MUG belongs to family 2 of the uracil-DNA glycosylase superfamily.[15]
ThymineDNAglycosylase(TDG)alsobelongstothesamefamily.Thisfamily
of MUG and TDG displays quite distinct properties, being insensitive to
inhibition by UGI and inactive on ss-uracil-DNA, and lacking the conserved
catalytic residues and speciﬁcity determinants of the Family-1 UDGs.[16]
When TFT is mispaired with guanine, MUG is able to excise the TFT
from the DNA, similar to BrdU and 5FU. Unlike BrdU and 5FU, however,
MUG was not able to recognize and remove TFT paired to adenine in the
double-strand DNA.
In vivo or ex vivo experiments using live cell cultures are very important,
and we plan to continue studying this mechanism. We believe that investi-
gation of the reactivity of several analogues incorporated into the DNA with
other DNA repair enzymes is a useful approach to identify new therapeutic
targets.904 N. Suzuki and M. Fukushima
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